Investigational drug · Phase 2
AHB-171
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hepatitis B, Chronic (CHB).
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "AHB-171"
First trial start
2026
Jun 24, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AHB-171", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatitis B, Chronic (CHB)
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "AHB-171" as an intervention, largest first.
- Study of AHB-171 in Chronic Hepatitis B ParticipantsPivotal-lookingNot yet recruiting
AusperBio Therapeutics Inc.Industry
NCT07617194 · 144 participants (planned) · Start Jul 6, 2026 · Primary completion Oct 8, 2027
Drug: AHB-171; Placebo matching [Investigational Product] and 1 more · For: Hepatitis B, Chronic
Sites: Hong Kong, Hong Kong; Grafton, New Zealand
Ausper Biopharma Co., Ltd.Industry
NCT07630727 · 138 participants (planned) · Start Jun 24, 2026 · Primary completion Mar 31, 2029
Drug: AHB-171 Injection · For: Hepatitis B, Chronic (CHB)
Sites: Beijing, China; Chongqing, China; Xiamen, China · 10 sites in all
- A Phase I Clinical Study of AHB - 171 in Healthy Participants(HP) and Chronic Hepatitis B (CHB) ParticipantsPivotal-lookingRecruiting
Ausper Biopharma Co., Ltd.Industry
NCT07511218 · 110 participants (planned) · Start Apr 13, 2026 · Primary completion Dec 30, 2027
Drug: AHB-171 Injection; Placebo and 1 more · For: Chronic Hepatitis B Infection
Sites: Ch’ang-ch’un, China; Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.